Temporal trends in small-cell lung cancer trials registered on ClinicalTrials.gov: a cross-sectional analysis (1996–2025)
Background Small-cell lung cancer (SCLC) has undergone important therapeutic advances in recent years, including the incorporation of programmed death-ligand 1 (PD-L1) inhibitors into first-line treatment for extensive-stage disease and the emergence of novel therapies for relapsed disease. Whether the characteristics...